SCHEMBL3497614

SCHEMBL3497614

CC(=O)OCCN1C(=O)C2(CCCN(C(=O)OC(C)(C)C)C2)CC1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.36
HRH3 Q9Y5N1 4/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
KDM1A O60341 2/20 0.34
BACE1 P56817 2/20 0.33
CTSD P07339 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRK1 P41145 1/20 0.33
OPRL1 P41146 1/20 0.33
HPGD P15428 1/20 0.33
MMP2 P08253 1/20 0.33
MMP13 P45452 1/20 0.33
MMP14 P50281 1/20 0.33
ADAM17 P78536 1/20 0.33
ELANE P08246 1/20 0.32
DDB1 Q16531 1/20 0.32
CRBN Q96SW2 1/20 0.32
PIK3R1 P27986 1/20 0.32
PIK3CA P42336 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3496804 0.94 USP30 (0.35) USP30HRH3GRIN2BGRIN2CKDM1A
SCHEMBL3497983 0.88 HRH3 (0.38) HRH3KDM1ABACE1CTSDHPGD
SCHEMBL14222817 0.87 GRIN2B (0.39) USP30HRH3GRIN2BGRIN2CKDM1A
SCHEMBL3497973 0.86 USP30 (0.37) USP30HRH3GRIN2BGRIN2CKDM1A
SCHEMBL3498100 0.85 USP30 (0.39) USP30HRH3GRIN2BGRIN2CKDM1A
SCHEMBL3495850 0.84 HPGD (0.38) USP30HRH3GRIN2BGRIN2CKDM1A
SCHEMBL14221991 0.84 USP30 (0.39) USP30HRH3GRIN2BGRIN2CKDM1A
SCHEMBL14222282 0.83 USP30 (0.38) USP30HRH3GRIN2BGRIN2CKDM1A
SCHEMBL3497703 0.82 BACE1 (0.40) USP30HRH3GRIN2BGRIN2CKDM1A
SCHEMBL3497446 0.82 USP30 (0.39) USP30HRH3GRIN2BGRIN2CKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160255-A1 SPIRO-CYCLIC COMPOUND ACACA, CPT1B, PC USP30 3125/4885HRH3 4836/4885GRIN2B 4231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.